Scarica l'app Stockscreener
1.85
1.07%
-0.02
Dopo l'orario di chiusura:
1.85
Precedente Chiudi:
$1.87
Aprire:
$1.98
Volume 24 ore:
4.53M
Relative Volume:
1.77
Capitalizzazione di mercato:
$111.34M
Reddito:
-
Utile/perdita netta:
$-33.85M
Rapporto P/E:
-3.2813
EPS:
-0.5638
Flusso di cassa netto:
$-33.35M
1 W Prestazione:
+30.28%
1M Prestazione:
-66.30%
6M Prestazione:
-62.63%
1 anno Prestazione:
-72.31%
Intervallo 1D:
$1.76
$2.02
Intervallo di 1 settimana:
$1.37
$2.33
Portata 52W:
$1.07
$6.73
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.85 | 112.54M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra ... - Bluefield Daily Telegraph
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
Does Aldeyra Therapeutics (ALDX) have the potential to rally 79.28% as Wall Street analysts expect? - MSN
BTIG Reiterates Aldeyra Therapeutics (ALDX) Buy Recommendation - MSN
Rosen Law Firm Investigating Potential Securities Claims Against Aldeyra Therapeutics - National Today
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), ... - Bluefield Daily Telegraph
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationALDX - Barchart.com
Insider Buying: Richard Douglas Acquires 70,000 Shares of Aldeyra Therapeutics Inc (ALDX) - GuruFocus
Aldeyra therapeutics director Douglas buys $98,000 in ALDX By Investing.com - Investing.com India
Insider Makes Bold Move on Aldeyra Therapeutics Stock - TipRanks
Insider Buying: Richard Douglas Acquires 70,000 Shares of Aldeyr - GuruFocus
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX - The Joplin Globe
ALDX PE Ratio & Valuation, Is ALDX Overvalued - Intellectia AI
Aldeyra therapeutics director Douglas buys $98,000 in ALDX - Investing.com
Director buys 70K Aldeyra Therapeutics (ALDX) shares at $1.40 - Stock Titan
Why Did ALDX Stock Tank 70% Today? - Stocktwits
ALDX crashes 71% as FDA issues third CRL for dry eye disease drug NDA - MSN
FDA rejects Aldeyra's dry eye drug for third time, stock crashes 68% - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock By Investing.com - Investing.com Australia
Insider Buying: Michael Alfieri Acquires Additional Shares of Al - GuruFocus
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock - Investing.com
Aldeyra Therapeutics (ALDX) finance chief buys 5,000 shares - Stock Titan
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects - marketscreener.com
What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
BTIG Maintains Buy on Aldeyra Therapeutics, Inc. (ALDX) March 2026 - Meyka
HC Wainwright & Co. downgrades Aldeyra Therapeutics (ALDX) - MSN
Aldeyra’s CEO to Lead Strategic Discussions at Healthcare Conference - StocksToTrade
Shareholder Alert: Ademi LLP Investigates Claims of Securities F - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) - The Globe and Mail
Aldeyra Eyes Growth as CEO Prepares for Key Conference - timothysykes.com
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc. - Barchart.com
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection - BioPharma Dive
ALDX Plummets 71% Following FDA's Third Complete Response Letter for Dry Eye Disease Drug Application - Bitget
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - The Globe and Mail
Upcoming Conference Sheds Light on Aldeyra Therapeutics’ Innovations - StocksToTrade
Aldeyra shares plunge after third FDA rejection for reproxalap - The Pharma Letter
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ALDX Stock Downgraded by HC Wainwright & Co. with Price Target R - GuruFocus
H.C. Wainwright cuts Aldeyra stock rating on FDA setback - Investing.com
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10 - marketscreener.com
FDA issues CRL to Aldeyra’s reproxalap drug application - Yahoo Finance
Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy DataHas The Bull Case Changed? - simplywall.st
FDA rejects Aldeyra’s dry eye disease drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalap - geneonline.com
Aldeyra Therapeutics (ALDX) Faces Major Setback as FDA Rejects E - GuruFocus
Aldeyra Therapeutics stock maintained at Buy by BTIG after FDA setback - Investing.com South Africa
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):